Anti-anginal Efficacy of Ticagrelor in Coronary Slow Flow

The CSFP is an angiographic finding characterised by the delayed passage of contrast through the coronary arteries, despite the absence of obstructive coronary artery disease (defined as less than 50% narrowing of the vessel lumen). Ticagrelor may serve as an effective anti-anginal therapy for these patients by increasing adenosine levels, which could alleviate coronary microvascular dysfunction and its associated angina due to its vasodilatory properties.

This study is designed as a double-­blind, placebo controlled, crossover study, to assess the effect of ticagrelor 90mg bd on angina frequency in patients with the Coronary Slow Flow Phenomenon (CSFP) who experience angina at least 3 times/week.

This asset includes data evaluating the anti-anginal efficacy of a 4-week ticagrelor therapy regimen in 20 CSFP patients with refractory angina. The mean age of patients 61.5 ± 10.5 years and 40% were women. Additionally, the asset includes the trial primary endpoint, which was the frequency of angina episodes, recorded using an angina diary. Secondary endpoints include the duration and severity of angina episodes, consumption of short-acting nitrates, and health status evaluations using the Seattle Angina Questionnaire (SAQ) and the Short Form-36 (SF-36) indices.

Results from the data asset are publicly available in an open-access publication: https://www.mdpi.com/2077-0383/13/17/5235

Requests in relation to this data asset should be made to the corresponding author. The data are not publicly available due to privacy and ethical restrictions.